Hematopoietic stem cell transplantation for hemoglobinopathies: Current practice and emerging trends

Pediatric Clinics of North America

Volumn 57, Issue 1, 2010, Pages 181-205

  Smiers, Frans J ^a   Krishnamurti, Lakshmanan ^b   Lucarelli, Guido ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c Mediterranean Institute of Hematology   (Italy)

Author keywords

Hematopoietic stem cell transplantation; Hemoglobinopathies; HSCT

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE MESYLATE; ERYTHROPOIETIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HYDROXYUREA; IRON CHELATING AGENT; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RIBAVIRIN; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE CHEST SYNDROME; ANEMIA; BETA THALASSEMIA; BONE MALFORMATION; BONE MARROW TRANSPLANTATION; BONE NECROSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHIMERA; CONTINUOUS INFUSION; CONVALESCENCE; CORD BLOOD STEM CELL TRANSPLANTATION; DEVELOPMENTAL DISORDER; DONOR SELECTION; DOSE RESPONSE; ERYTHROCYTE TRANSFUSION; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GROWTH DISORDER; HEALTH CARE PRACTICE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHY; HEMOLYSIS; HLA MATCHING; HUMAN; IRON OVERLOAD; LEUKOPENIA; LOW DRUG DOSE; OVARY INSUFFICIENCY; PARENTAL ATTITUDE; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; REDUCED INTENSITY CONDITIONING; RESPIRATORY DISTRESS; REVIEW; RISK ASSESSMENT; SEPSIS; SICKLE CELL ANEMIA; SIDE EFFECT; SPERMATOGENESIS; SURVIVAL RATE; THALASSEMIA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHIES; HEMOGLOBINS; HUMANS; PUBLIC HEALTH; QUALITY OF LIFE;

EID: 77951137730     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2010.01.003     Document Type: Review

References (173)

1. Giardine B., van B.S., Kaimakis P., et al. HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update. Hum Mutat 2007, 28(2):206.
2. Pootrakul P., Sirankapracha P., Hemsorach S., et al. A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in Thai patients with thalassemia. Blood 2000, 96(7):2606-2612.
3. Weatherall D.J. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet 2001, 2(4):245-255.
4. Kong Y., Zhou S., Kihm A.J., et al. Loss of alpha-hemoglobin-stabilizing protein impairs erythropoiesis and exacerbates beta-thalassemia. J Clin Invest 2004, 114(10):1457-1466.
5. Centis F., Tabellini L., Lucarelli G., et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood 2000, 96(10):3624-3629.
6. Mathias L.A., Fisher T.C., Zeng L., et al. Ineffective erythropoiesis in beta-thalassemia major is due to apoptosis at the polychromatophilic normoblast stage. Exp Hematol 2000, 28(12):1343-1353.
7. Rivella S. Ineffective erythropoiesis and thalassemias. Curr Opin Hematol 2009, 16(3):187-194.
8. Chen J.J. Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to anemias. Blood 2007, 109(7):2693-2699.
9. Libani I.V., Guy E.C., Melchiori L., et al. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. Blood 2008, 112(3):875-885.
10. Finch C. Regulators of iron balance in humans. Blood 1994, 84(6):1697-1702.
11. Cunningham M.J., Macklin E.A., Neufeld E.J., et al. Complications of beta-thalassemia major in North America. Blood 2004, 104(1):34-39.
12. Vogiatzi M.G., Macklin E.A., Fung E.B., et al. Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 2009, 24(3):543-557.
13. Olivieri N.F., Brittenham G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 1997, 89(3):739-761.
14. Olivieri N.F., Brittenham G.M., McLaren C.E., et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998, 339(7):417-423.
15. Koren A., Levin C., Dgany O., et al. Response to hydroxyurea therapy in beta-thalassemia. Am J Hematol 2008, 83(5):366-370.
16. Zamani F., Shakeri R., Eslami S.M., et al. Hydroxyurea therapy in 49 patients with major beta-thalassemia. Arch Iran Med 2009, 12(3):295-297.
17. Olivieri N.F., Rees D.C., Ginder G.D., et al. Elimination of transfusions through induction of fetal hemoglobin synthesis in Cooley's anemia. Ann N Y Acad Sci 1998, 850:100-109.
18. Yavarian M., Karimi M., Bakker E., et al. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. Haematologica 2004, 89(10):1172-1178.
19. Borgna-Pignatti C., Cappellini M.D., De S.P., et al. Survival and complications in thalassemia. Ann N Y Acad Sci 2005, 1054:40-47.
20. Borgna-Pignatti C., Cappellini M.D., De S.P., et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006, 107(9):3733-3737.
21. Ehlers K.H., Giardina P.J., Lesser M.L., et al. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr 1991, 118(4 Pt 1):540-545.
22. Brittenham G.M., Griffith P.M., Nienhuis A.W., et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994, 331(9):567-573.
23. Modell B., Letsky E.A., Flynn D.M., et al. Survival and desferrioxamine in thalassaemia major. Br Med J (Clin Res Ed) 1982, 284(6322):1081-1084.
24. Modell B., Khan M., Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia register. Lancet 2000, 355(9220):2051-2052.
25. Delea T.E., Edelsberg J., Sofrygin O., et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007, 47(10):1919-1929.
26. Anderson L.J., Holden S., Davis B., et al. Cardiovascular T2-star (T2) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001, 22(23):2171-2179.
27. Bunn H.F. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997, 337(11):762-769.
28. Stuart M.J., Nagel R.L. Sickle-cell disease. Lancet 2004, 364(9442):1343-1360.
29. Reiter C.D., Wang X., Tanus-Santos J.E., et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002, 8(12):1383-1389.
30. Wang X., Tanus-Santos J.E., Reiter C.D., et al. Biological activity of nitric oxide in the plasmatic compartment. Proc Natl Acad Sci U S A 2004, 101(31):11477-11482.
31. Belhassen L., Pelle G., Sediame S., et al. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 2001, 97(6):1584-1589.
32. Bakare M.O., Omigbodun O.O., Kuteyi O.B., et al. Psychological complications of childhood chronic physical illness in Nigerian children and their mothers: the implication for developing pediatric liaison services. Child Adolesc Psychiatry Ment Health 2008, 2(1):34.
33. Benton T.D., Ifeagwu J.A., Smith-Whitley K. Anxiety and depression in children and adolescents with sickle cell disease. Curr Psychiatry Rep 2007, 9(2):114-121.
34. Levenson J.L., McClish D.K., Dahman B.A., et al. Depression and anxiety in adults with sickle cell disease: the PiSCES project. Psychosom Med 2008, 70(2):192-196.
35. Pham P.T., Pham P.C., Wilkinson A.H., et al. Renal abnormalities in sickle cell disease. Kidney Int 2000, 57(1):1-8.
36. Wigfall D.R., Ware R.E., Burchinal M.R., et al. Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease. J Pediatr 2000, 136(6):749-753.
37. Bruno D., Wigfall D.R., Zimmerman S.A., et al. Genitourinary complications of sickle cell disease. J Urol 2001, 166(3):803-811.
38. Fowler J.E., Koshy M., Strub M., et al. Priapism associated with the sickle cell hemoglobinopathies: prevalence, natural history and sequelae. J Urol 1991, 145(1):65-68.
39. Mantadakis E., Cavender J.D., Rogers Z.R., et al. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol 1999, 21(6):518-522.
40. Miller S.T., Rao S.P., Dunn E.K., et al. Priapism in children with sickle cell disease. J Urol 1995, 154(2 Pt 2):844-847.
41. Platt O.S., Brambilla D.J., Rosse W.F., et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994, 330(23):1639-1644.
42. Gladwin M.T., Sachdev V., Jison M.L., et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004, 350(9):886-895.
43. Machado R.F., Gladwin M.T. Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol 2005, 129(4):449-464.
44. Bridges W. Cerebral vascular disease accompanying sickle cell anemia. Am J Pathol 1939, 15:353-360.
45. Ohene-Frempong K., Weiner S.J., Sleeper L.A., et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998, 91(1):288-294.
46. Miller S.T., Macklin E.A., Pegelow C.H., et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr 2001, 139(3):385-390.
47. Kugler S., Anderson B., Cross D., et al. Abnormal cranial magnetic resonance imaging scans in sickle-cell disease. Neurological correlates and clinical implications. Arch Neurol 1993, 50(6):629-635.
48. Seibert J.J., Miller S.F., Kirby R.S., et al. Cerebrovascular disease in symptomatic and asymptomatic patients with sickle cell anemia: screening with duplex transcranial Doppler US-correlation with MR imaging and MR angiography. Radiology 1993, 189(2):457-466.
49. Seibert J.J., Glasier C.M., Kirby R.S., et al. Transcranial Doppler, MRA, and MRI as a screening examination for cerebrovascular disease in patients with sickle cell anemia: an 8-year study. Pediatr Radiol 1998, 28(3):138-142.
50. Adams R., McKie V., Nichols F., et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med 1992, 326(9):605-610.
51. Adams R.J., Nichols F.T., Figueroa R., et al. Transcranial Doppler correlation with cerebral angiography in sickle cell disease. Stroke 1992, 23(8):1073-1077.
52. Adams R.J., McKie V.C., Carl E.M., et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol 1997, 42(5):699-704.
53. Adams R.J., McKie V.C., Brambilla D., et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials 1998, 19(1):110-129.
54. Adams R.J., McKie V.C., Hsu L., et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998, 339(1):5-11.
55. Adams R.J. Stroke prevention in sickle cell disease. Curr Opin Hematol 2000, 7(2):101-105.
56. Charache S., Terrin M.L., Moore R.D., et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995, 332(20):1317-1322.
57. Ferster A., Tahriri P., Vermylen C., et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001, 97(11):3628-3632.
58. Hankins J.S., Ware R.E., Rogers Z.R., et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 2005, 106(7):2269-2275.
59. Sumoza A., de B.R., Sumoza D., et al. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am J Hematol 2002, 71(3):161-165.
60. Ware R.E., Zimmerman S.A., Schultz W.H. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999, 94(9):3022-3026.
61. Ware R.E., Zimmerman S.A., Sylvestre P.B., et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 2004, 145(3):346-352.
62. Berthaut I., Guignedoux G., Kirsch-Noir F., et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 2008, 93(7):988-993.
63. Jones K.M., Niaz M.S., Brooks C.M., et al. Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints. Int J Environ Res Public Health 2009, 6(3):1124-1144.
64. Lukusa A.K., Vermylen C., Vanabelle B., et al. Bone marrow transplantation or hydroxyurea for sickle cell anemia: long-term effects on semen variables and hormone profiles. Pediatr Hematol Oncol 2009, 26(4):186-194.
65. Quinn C.T., Rogers Z.R., Buchanan G.R. Survival of children with sickle cell disease. Blood 2004, 103(11):4023-4027.
66. Serjeant G.R. Sickle-cell disease. Lancet 1997, 350(9079):725-730.
67. Gill F.M., Sleeper L.A., Weiner S.J., et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 1995, 86(2):776-783.
68. Giardini C., Lucarelli G. Bone marrow transplantation for beta-thalassemia. Hematol Oncol Clin North Am 1999, 13(5):1059-1064. viii.
69. Lucarelli G., Galimberti M., Polchi P., et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990, 322(7):417-421.
70. Lucarelli G., Galimberti M., Polchi P., et al. Bone marrow transplantation in thalassemia. Hematol Oncol Clin North Am 1991, 5(3):549-556.
71. Sodani P., Gaziev D., Polchi P., et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 2004, 104(4):1201-1203.
72. Lucarelli G., Galimberti M., Polchi P., et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993, 329(12):840-844.
73. Lucarelli G., Clift R.A., Galimberti M., et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996, 87(5):2082-2088.
74. Lucarelli G., Andreani M., Angelucci E. The cure of thalassemia by bone marrow transplantation. Blood Rev 2002, 16(2):81-85.
75. Lucarelli G., Galimberti M., Polchi P., et al. Bone marrow transplantation in adult thalassemia. Blood 1992, 80(6):1603-1607.
76. Lucarelli G., Clift R.A., Galimberti M., et al. Bone marrow transplantation in adult thalassemic patients. Blood 1999, 93(4):1164-1167.
77. Gaziev J., Sodani P., Polchi P., et al. Bone marrow transplantation in adults with thalassemia: treatment and long-term follow-up. Ann N Y Acad Sci 2005, 1054:196-205.
78. Andreani M., Manna M., Lucarelli G., et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996, 87(8):3494-3499.
79. Andreani M., Nesci S., Lucarelli G., et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 2000, 25(4):401-404.
80. Lisini D., Zecca M., Giorgiani G., et al. Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling. Haematologica 2008, 93(12):1859-1867.
81. Locatelli F. Tolerance: pregnancy matters. Blood 2009, 114(11):2208-2209.
82. Serafini G., Andreani M., Testi M., et al. Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia. Haematologica 2009, 94(10):1415-1426.
83. van Halteren A.G., Jankowska-Gan E., Joosten A., et al. Naturally acquired tolerance and sensitization to minor histocompatibility antigens in healthy family members. Blood 2009, 114(11):2263-2272.
84. Gaziev D., Polchi P., Lucarelli G., et al. Second marrow transplants for graft failure in patients with thalassemia. Bone Marrow Transplant 1999, 24(12):1299-1306.
85. Gaziev J., Sodani P., Lucarelli G., et al. Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Bone Marrow Transplant 2008, 42(6):397-404.
86. Gaziev D., Polchi P., Galimberti M., et al. Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors. Transplantation 1997, 63(6):854-860.
87. Lucarelli G., Angelucci E., Giardini C., et al. Fate of iron stores in thalassaemia after bone-marrow transplantation. Lancet 1993, 342(8884):1388-1391.
88. Angelucci E., Muretto P., Nicolucci A., et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002, 100(1):17-21.
89. Angelucci E., Muretto P., Lucarelli G., et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood 1997, 90(3):994-998.
90. Angelucci E., Muretto P., Lucarelli G., et al. Treatment of iron overload in the " ex-thalassemic" Report from the phlebotomy program. Ann N Y Acad Sci 1998, 850:288-293.
91. Giardini C., Galimberti M., Lucarelli G., et al. Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia. Br J Haematol 1995, 89(4):868-873.
92. Mariotti E., Angelucci E., Agostini A., et al. Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. Br J Haematol 1998, 103(4):916-921.
93. Gaziev J., Galimberti M., Giardini C., et al. Growth in children after bone marrow transplantation for thalassemia. Bone Marrow Transplant 1993, 12(Suppl 1):100-101.
94. De Sanctis V., Galimberti M., Lucarelli G., et al. Growth and development in ex-thalassemic patients. Bone Marrow Transplant 1997, 19(Suppl 2):126-127.
95. Borgna-Pignatti C., Marradi P., Rugolotto S., et al. Successful pregnancy after bone marrow transplantation for thalassaemia. Bone Marrow Transplant 1996, 18(1):235-236.
96. Strader D.B., Wright T., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39(4):1147-1171.
97. Walters M.C., Patience M., Leisenring W., et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996, 335(6):369-376.
98. Adams R.J., Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005, 353(26):2769-2778.
99. Aduloju S., Palmer S., Eckman J. Mortality in sickle cell patient transitioning from pediatric to adult program: 10 years Grady comprehensive sickle cell center experience [abstract 1426]. Blood 2008, 112.
100. Powars D.R., Chan L.S., Hiti A., et al. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) 2005, 84(6):363-376.
101. Walters M.C., Patience M., Leisenring W., et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 1996, 2(2):100-104.
102. Kodish E., Lantos J., Stocking C., et al. Bone marrow transplantation for sickle cell disease. A study of parents' decisions. N Engl J Med 1991, 325(19):1349-1353.
103. van Besien K., Koshy M., nderson-Shaw L., et al. Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions. Bone Marrow Transplant 2001, 28(6):545-549.
104. Bernaudin F, Vernant JP, Vilmer E, et al. Results of allogeneic stem cell transplant for severe sickle cell disease (SCD) in France and consideration about conditioning regimen and indications in 2002. 30th Anniversary of the National Sickle Cell Disease Program National Heart, Lung, and Blood Institute National Institutes of Health and the Sickle Cell Association of America Inc, Washington Hilton and Towers, Washington, DC 2002;33.
105. Ferster A., Corazza F., Vertongen F., et al. Transplanted sickle-cell disease patients with autologous bone marrow recovery after graft failure develop increased levels of fetal haemoglobin which corrects disease severity. Br J Haematol 1995, 90(4):804-808.
106. Vermylen C., Fernandez R.E., Ninane J., et al. Bone marrow transplantation in five children with sickle cell anaemia. Lancet 1988, 1(8600):1427-1428.
107. Abboud M., Kletzl M., Miller S., et al. Bone marrow transplantation for sickle cell disease. Blood 1997, 90:229a.
108. Abboud M.R., Jackson S.M., Barredo J., et al. Bone marrow transplantation for sickle cell anemia. Am J Pediatr Hematol Oncol 1994, 16(1):86-89.
109. Bernaudin F., Souillet G., Vannier J.P., et al. Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): the French experience. GEGMO. Bone Marrow Transplant 1993, 12(Suppl 1):118-121.
110. Bernaudin F. Pathol Biol (Paris) 1999, 47(1):59-64. [in French].
111. Brichard B., Vermylen C., Ninane J., et al. Persistence of fetal hemoglobin production after successful transplantation of cord blood stem cells in a patient with sickle cell anemia. J Pediatr 1996, 128(2):241-243.
112. Giardini C., Galimberti M., Lucarelli G., et al. Bone marrow transplantation in sickle-cell anemia in Pesaro. Bone Marrow Transplant 1993, 12(Suppl 1):122-123.
113. Golden F. The sickle-cell kid. An experimental transplant succeeds, giving a brave little boy the best Christmas present he can imagine. Times 1999, 154(25):92.
114. Gore L., Lane P.A., Quinones R.R., et al. Successful cord blood transplantation for sickle cell anemia from a sibling who is human leukocyte antigen-identical: implications for comprehensive care. J Pediatr Hematol Oncol 2000, 22(5):437-440.
115. Hoppe C.C., Walters M.C. Bone marrow transplantation in sickle cell anemia. Curr Opin Oncol 2001, 13(2):85-90.
116. Locatelli F., Rocha V., Reed W., et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003, 101(6):2137-2143.
117. Vermylen C., Cornu G., Ferster A., et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998, 22(1):1-6.
118. Walters M.C., Storb R., Patience M., et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000, 95(6):1918-1924.
119. Werner E., Yanovich S., Rubinstein P., et al. Unrelated placental cord blood transplantation in a patient with sickle cell disease and acute non-lymphocytic leukemia. Blood 1997, 90:4542. 399b.
120. Bernaudin F., Socie G., Kuentz M., et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007, 110(7):2749-2756.
121. Walters M.C., Patience M., Leisenring W., et al. Updated results of bone marrow transplantation (BMT) for sickle cell disease (SCD): impact on CNS disease. Blood 2002, 100(46):160. p45a.
122. Adamkiewicz T, Chiang KY, Haight A, et al. Significant progression of large central nervous system (CNS) vessel disease following G Full matched sibling marrow engraftment in a child with hemoglobin SS. 30th Anniversary of the National Sickle Cell Disease Program National Heart, Lung, and Blood Institute. National Institutes of Health and the Sickle Cell Disease Association of America Inc, Washington Hilton and Towers, Washington, DC 2002;(1).
123. Horan j, Liesveld J, Fenton P, et al. Hematopoietic stem cell transplantation for sickle cell disease and thalassemia after low dos TBI, Fludarabine and rabbit ATG. 30th Anniversary of the National Sickle Cell Disease Program National Heart, Lung and Blood Institute. National Institutes of Health and the Sickle Cell Disease Association of America Inc, Washington Hilton and Towers, Washington, DC, 2002;34.
124. Kalinyak K.A., Morris C., Ball W.S., et al. Bone marrow transplantation in a young child with sickle cell anemia. Am J Hematol 1995, 48(4):256-261.
125. Steen R.G., Helton K.J., Horwitz E.M., et al. Improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts. Ann Neurol 2001, 49(2):222-229.
126. Eggleston B., Patience M., Edwards S., et al. Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia. Br J Haematol 2007, 136(4):673-676.
127. Hernigou P., Bernaudin F., Reinert P., et al. Bone-marrow transplantation in sickle-cell disease. Effect on osteonecrosis: a case report with a four-year follow-up. J Bone Joint Surg Am 1997, 79(11):1726-1730.
128. Ferster A., Bujan W., Corazza F., et al. Bone marrow transplantation corrects the splenic reticuloendothelial dysfunction in sickle cell anemia. Blood 1993, 81(4):1102-1105.
129. Walters M.C. Sickle cell anemia and hematopoietic cell transplantation: When is a pound of cure worth more than an ounce of prevention?. Pediatr Transplant 2004, 8(Suppl 5):33-38.
130. Steen R.G., Emudianughe T., Hankins G.M., et al. Brain imaging findings in pediatric patients with sickle cell disease. Radiology 2003, 228(1):216-225.
131. Woodard P., Helton K.J., Khan R.B., et al. Brain parenchymal damage after haematopoietic stem cell transplantation for severe sickle cell disease. Br J Haematol 2005, 129(4):550-552.
132. Baron F., Sandmaier B.M. Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Curr Opin Hematol 2005, 12(6):435-443.
133. Champlin R., Khouri I., Anderlini P., et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Williston Park) 2003, 17(1):94-100.
134. Chao N.J., Liu C.X., Rooney B., et al. Nonmyeloablative regimen preserves " niches" allowing for peripheral expansion of donor T-cells. Biol Blood Marrow Transplant 2002, 8(5):249-256.
135. Mielcarek M., Sandmaier B.M., Maloney D.G., et al. Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives. J Clin Immunol 2002, 22(2):70-74.
136. Resnick I.B., Shapira M.Y., Slavin S. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. Transpl Immunol 2005, 14(3-4):207-219.
137. Shimoni A., Nagler A. Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience. Curr Hematol Rep 2004, 3(4):242-248.
138. Slavin S., Or R., Aker M., et al. Nonmyeloablative stem cell transplantation for the treatment of cancer and life-threatening nonmalignant disorders: past accomplishments and future goals. Cancer Chemother Pharmacol 2001, 48(Suppl 1):S79-S84.
139. Storb R.F., Lucarelli G., McSweeney P.A., et al. Hematopoietic cell transplantation for benign hematological disorders and solid tumors. Hematology Am Soc Hematol Educ Program 2003, 372-397.
140. Walters M.C., Patience M., Leisenring W., et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 2001, 7(12):665-673.
141. Storb R.F., Champlin R., Riddell S.R., et al. Non-myeloablative transplants for malignant disease. Hematology Am Soc Hematol Educ Program 2001, 375-391.
142. Miniero R., Rocha V., Saracco P., et al. Cord blood transplantation (CBT) in hemoglobinopathies. Eurocord. Bone Marrow Transplant 1998, 22(Suppl 1):S78-S79.
143. Hongeng S., Chuansumrit A., Hathirat P., et al. Full chimerism in nonmyeloablative stem cell transplantation in a beta-thalassemia major patient (class 3 Lucarelli). Bone Marrow Transplant 2002, 30(6):409-410.
144. Krishnamurti L., Blazar B.R., Wagner J.E. Bone marrow transplantation without myeloablation for sickle cell disease. N Engl J Med 2001, 344(1):68.
145. Schleuning M., Stoetzer O., Waterhouse C., et al. Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease. Exp Hematol 2002, 30(1):7-10.
146. Shenoy S., Grossman W.J., DiPersio J., et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant 2005, 35(4):345-352.
147. van Besien K., Bartholomew A., Stock W., et al. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant 2000, 26(4):445-449.
148. Horan J.T., Liesveld J.L., Fenton P., et al. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant 2005, 35(2):171-177.
149. Iannone R., Casella J.F., Fuchs E.J., et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003, 9(8):519-528.
150. Woolfrey A.E., Pulsipher M.A., Storb R. Non-myeloablative hematopoietic cell transplant for treatment of nonmalignant disorders in children. Int J Hematol 2002, 76(Suppl 2):271-277.
151. Krishnamurti L., Wu C.J., Baker K.S., et al. Matched sibling donor hematopoietic cell transplantation for sickle cell disease using a reduced intensity conditioning regimen can lead to stable long term engraftment [abstract 3172]. Blood 2005, 106.
152. Dodero A., Carrabba M., Milani R., et al. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol 2005, 33(8):920-927.
153. Avivi I., Chakrabarti S., Kottaridis P., et al. Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. Bone Marrow Transplant 2004, 34(2):137-142.
154. Iannone R., Luznik L., Engstrom L.W., et al. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia. Blood 2001, 97(12):3960-3965.
155. Kean L.S., Manci E.A., Perry J., et al. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. Blood 2003, 102(13):4582-4593.
156. Wu C.J., Krishnamurti L., Kutok J.L., et al. Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood 2005, 106(10):3639-3645.
157. Reed W., Smith R., Dekovic F., et al. Comprehensive banking of sibling donor cord blood for children with malignant and nonmalignant disease. Blood 2003, 101(1):351-357.
158. Krishnamurti L., Bunn H.F., Williams A.M., et al. Hematopoietic cell transplantation for hemoglobinopathies. Curr Probl Pediatr Adolesc Health Care 2008, 38(1):6-18.
159. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91(3):756-763.
160. Isola L.M., Chao N.J., Weinberg R.S., et al. Donor chimerism after T-cell depleted (TCD)-non-myeloablative allogeneic SCT (NST) in hemoglobinopathies. Blood 2002, 100(11). part 2.
161. La N.G., Giardini C., Argiolu F., et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood 2002, 99(12):4350-4356.
162. La N.G., Argiolu F., Giardini C., et al. Unrelated bone marrow transplantation for beta-thalassemia patients: the experience of the Italian Bone Marrow Transplant Group. Ann N Y Acad Sci 2005, 1054:186-195.
163. Hongeng S., Pakakasama S., Chuansumrit A., et al. Outcomes of transplantation with related- and unrelated-donor stem cells in children with severe thalassemia. Biol Blood Marrow Transplant 2006, 12(6):683-687.
164. Sodani P., Isgro A., Gaziev J., et al. Purified T-depleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. Blood 2009, [Epub ahead of print].
165. Chakraverty R., Peggs K., Chopra R., et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002, 99(3):1071-1078.
166. Adamkiewicz T., Mehta P.S., Boyer M.W., et al. Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease. Bone Marrow Transplant 2004, 34(5):405-411.
167. Krishnamurti L., Abel S., Maiers M., et al. Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. Bone Marrow Transplant 2003, 31(7):547-550.
168. Adamkiewicz T., Boyer M.W., Bray R., et al. Identification of unrelated cord blood units for hematopoietic stem cell transplantation in children with sickle cell disease. J Pediatr Hematol Oncol 2006, 28(1):29-32.
169. Myaskovsky L., Switzer G.E., Dew M.A., et al. The association of donor center characteristics with attrition from the national marrow donor registry. Transplantation 2004, 77(6):874-880.
170. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004, 104(7):1923-1930.
171. Barker J.N., Weisdorf D.J., Wagner J.E. Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. N Engl J Med 2001, 344(24):1870-1871.
172. Miller S.T., Sleeper L.A., Pegelow C.H., et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000, 342(2):83-89.
173. Shpall E.J., Quinones R., Giller R., et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 2002, 8(7):368-376.